Guidelines from the National Institute for Health and Care Excellence (NICE) offer a unique perspective on diagnosis and management of menopause. Plus: A guide for hormone replacement therapy.
NICE guidelines on menopause
Guidelines from the National Institute for Health and Care Excellence (NICE) offer a unique perspective on diagnosis and management of menopause, designed to help women stop suffering in silence. Aimed at health care providers in the UK but also relevant to US ob/gyns, the recommendations focus on ways to determine if menopause has started, what drug and non-drug options might be useful for a patient’s physical and psychological symptoms, and clarifying the risks and benefits of hormone replacement therapy (HRT).The NICE Guideline: Diagnosis and Management of the Menopause contains 10 key messages:
NICE is an independent body responsible for driving improvement and excellence in the UK health and social care system. The organization develops guidance, standards and information on high-quality health and social care and advises on ways to promote healthy living and prevent ill health.
The NICE guideline on menopause for health care providers is available at http://www.nice.org.uk/guidance/NG23.
NEXT: Post NICE guide for HRT
Post NICE guide for hormone replacement therapy
The safety of hormone replacement therapy (HRT) depends largely on the age of the patient. For most women, the risks are few and the potential benefits are many when HRT is given for clear indications and therapy is initiated within a few years of menopause.
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.
Read More
Study links premature menopause to musculoskeletal pain and sarcopenia risks
May 1st 2024A recent study revealed an association between premature menopause and increased risks of musculoskeletal pain and sarcopenia, emphasizing the potential benefits of hormone therapy in mitigating long-term effects.
Read More